Environmental risk assessment in the EU regulation of medicines for human use: an analysis of stakeholder perspectives on its current and future role

Jim F. Zinken,Anna M.G. Pasmooij,Antwan G.H. Ederveen,Jarno Hoekman,Lourens T. Bloem
DOI: https://doi.org/10.1016/j.drudis.2024.104213
IF: 8.369
2024-10-22
Drug Discovery Today
Abstract:An environmental risk assessment (ERA) is mandatory for all applications for marketing authorisation of medicines in the European Union (EU). We investigated stakeholder perspectives on the role of the ERA in EU regulation of medicines for human use. We discuss the current position of the ERA, including the conduct and assessment of the ERA, such as the required expertise, data, and studies, its applicability to generic drugs, and its use in regulatory decision-making. We also discuss future...
pharmacology & pharmacy
What problem does this paper attempt to address?